Three neuromodulation therapies have been appropriately tested and approved in refractory
focal epilepsies: vagus nerve stimulation (VNS), deep brain stimulation of the anterior …

Background Vagus nerve stimulation (VNS) is approved as an adjunctive treatment for drug-
resistant epilepsy. Although there is a substantial amount of literature aiming at unraveling …

Cumulative evidence suggests that pyroptosis, a new sort of programmed cell death, is
closely related to cerebral ischemia/reperfusion (I/R) injury. Our previous studies have …

Drug‐resistant epilepsy (DRE) considerably affects patient health, cognition, and well‐
being, and disproportionally contributes to the overall burden of epilepsy. The most common …

The vagus nerve stimulation (VNS) Therapy® System is the first FDA-approved medical
device therapy for the treatment of drug-resistant epilepsy. Over the past two decades, the …

Three neuromodulation therapies, all using implanted device and electrodes, have been
approved to treat adults with drug-resistant focal epilepsy, namely, the vagus nerve …

Although vagus nerve stimulation (VNS) is a common procedure, seizure outcomes are
heterogeneous, with few available means to preoperatively identify the ideal surgical …

Epilepsy is a common neurological disorder characterized by recurrent and disabling
seizures. An increasing number of clinical and experimental applications of machine …

Introduction: VNS is an adjunctive neuromodulation therapy for patients with drug-refractory
epilepsy. The antiseizure effect of VNS is thought to be related to a diffuse modulation of …

Epilepsy is a common neurological disorder associated with alterations in cortical and
subcortical brain networks. Despite a historical focus on gray matter regions involved in …